| These highlights do not include all the information needed to use ATTERO™ Topical Suspension, safely and effectively. See full prescribing information for ATTERO™ Topical Suspension. Attero™ (calcipotriene and betamethasone dipropionate) topical suspension Initial U.S. Approval: 2006 | Perfero Pharma, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20260518 | 1 |
| Pellix™ (calcipotriene) Topical Solution, 0.005% (Scalp Solution) | Perfero Pharma, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20260504 | 2 |
| Cipotrex | V2 Pharma, LLC | V2 Pharma LLC | 20260325 | 1 |
| Calyxra | Florrax Pharmaceutical | 20260324 | 2 |
| Calcipotriene Ointment USP, 0.005% | Glenmark Pharmaceuticals Inc., USA | Glenmark Pharmaceuticals Limited | 20260123 | 9 |
| CALCIPOTRIENE CREAM USP, 0.005% | Glenmark Pharmaceuticals Inc.,USA | Glenmark Pharmaceuticals Limited | 20251027 | 7 |
| These highlights do not include all the information needed to use CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE TOPICAL SUSPENSION safely and effectively. See full prescribing information for CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE TOPICAL SUSPENSION. CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE, for topical suspension Initial U.S. Approval: 2006 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc. | 20250701 | 2 |
| Calcipotriene Ointment, 0.005% | Taro Pharmaceuticals U.S.A., Inc. | Glenmark Generics Ltd. | 20241210 | 4 |
| These highlights do not include all the information needed to use CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE TOPICAL SUSPENSION, 0.005%/0.064% safely and effectively. See full prescribing information for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE TOPICAL SUSPENSION, 0.005%/0.064% . CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE topical suspension, 0.005%/0.064% Initial U.S. Approval: 2006 | Cosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20240813 | 2 |
| CALCIPOTRIENE CREAM USP, 0.005% | Northstar Rx LLC | Glenmark Pharmaceuticals Limited | 20240624 | 4 |
| These highlights do not include all the information needed to use calcipotriene foam safely and effectively. See full prescribing information for calcipotriene foam. CALCIPOTRIENE foam, for topical use Initial U.S. Approval: 1993 | Mayne Pharma | DPT Laboratories, Ltd. | 20240509 | 4 |
| These highlights do not include all the information needed to use SORILUX safely and effectively. See full prescribing information for SORILUX. SORILUX (calcipotriene) foam, for topical use Initial U.S. Approval: 1993 | Mayne Pharma | DPT Laboratories, Ltd. | 20240509 | 7 |
| These highlights do not include all the information needed to use CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT safely and effectively. See Full Prescribing Information for CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT . CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE ointment, for topical use Initial U.S. Approval: 2006 | Padagis Israel Pharmaceuticals Ltd | 20240430 | 7 |
| These highlights do not include all the information needed to use CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT safely and effectively. See Full Prescribing Information for CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT . CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE ointment, for topical use Initial U.S. Approval: 2006 | Bryant Ranch Prepack | 20240208 | 101 |
| These highlights do not include all the information needed to use CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT safely and effectively. See Full Prescribing Information for CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT . CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE ointment, for topical use Initial U.S. Approval: 2006 | Bryant Ranch Prepack | 20231207 | 103 |
| These highlights do not include all the information needed to use WYNZORA Cream safely and effectively. See full prescribing information for WYNZORA Cream. WYNZORA ® (calcipotriene and betamethasone dipropionate) cream, for topical use Initial U.S. Approval: 2020 | MC2 Therapeutics Ltd | 20231129 | 6 |
| These highlights do not include all the information needed to use CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT safely and effectively. See Full Prescribing Information for CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE OINTMENT . CALCIPOTRIENE and BETAMETHASONE DIPROPIONATE ointment, for topical use Initial U.S. Approval: 2006 | Bryant Ranch Prepack | 20230717 | 103 |
| Trionex | V2 Pharma, LLC | 20230113 | 10 |
| Calcipotriene Cream, 0.005% | Prasco Laboratories | LEO Laboratories Ltd. | 20221212 | 10 |
| These highlights do not include all the information needed to use Calcipotriene and Betamethasone Dipropionate Ointment safely and effectively. See Full Prescribing Information for Calcipotriene and Betamethasone Dipropionate Ointment. Calcipotriene and Betamethasone Dipropionate Ointment, for topical use Initial U.S. Approval: 2006 | Prasco Laboratories | LEO Pharma Inc. | LEO Laboratories Ltd. | 20221212 | 5 |
| Calcipotriene Topical Solution, 0.005% (Scalp Solution) Rx only FOR TOPICAL DERMATOLOGIC USE ONLY. Not for Ophthalmic, Oral or Intravaginal Use. | Cosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20221115 | 10 |
| These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR ® (calcipotriene and betamethasone dipropionate) foam, for topical use Initial U.S. Approval: 2006 | LEO Pharma Inc. | LEO Laboratories Ltd. | 20211018 | 15 |
| a838204b-9564-9aa6-e053-2a95a90af02f | NuCare Pharmaceuticals,Inc. | 20210504 | 2 |
| a837f13e-fafc-0535-e053-2995a90a5070 | NuCare Pharmaceuticals,Inc. | 20210503 | 2 |
| Calcipotriene Ointment, 0.005% FOR TOPICAL DERMATOLOGIC USE ONLY. Not for Ophthalmic, Oral or Intravaginal Use. Rx only | Prasco Laboratories | LEO Laboratories Ltd. | 20200807 | 9 |
| 89f6689b-ef95-613b-e053-2a95a90ac161 | NuCare Pharmaceuticals,Inc. | 20190528 | 1 |
| 89a98b7c-d36b-6016-e053-2a95a90aa31b | NuCare Pharmaceuticals,Inc. | 20190524 | 1 |
| CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05% | Sincerus Florida, LLC | 20190520 | 1 |
| CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05% | Sincerus Florida, LLC | 20190520 | 1 |
| CALCIPOTRIENE 0.005% / NIACINAMIDE 4% | Sincerus Florida, LLC | 20190513 | 1 |
| CALCIPOTRIENE 0.005% / TRIAMCINOLONE ACETONIDE 0.1% | Sincerus Florida, LLC | 20190510 | 1 |
| CALCIPOTRIENE 0.005% / DICLOFENAC SODIUM 3% / HYALURONIC ACID SODIUM SALT 2% / NIACINAMIDE 2% | Sincerus Florida, LLC | 20190506 | 1 |
| Calcitrene ® (Calcipotriene) Ointment 0.005% | Taro Pharmaceuticals U.S.A., Inc. | Glenmark Generics Ltd. | 20190123 | 3 |
| Calcipotriene Topical Solution, 0.005% (Scalp Solution) Rx only FOR TOPICAL DERMATOLOGIC USE ONLY. Not for Ophthalmic, Oral or Intravaginal Use. | Novel Laboratories, Inc. | 20181203 | 2 |
| These highlights do not include all the information needed to use TACLONEX Topical Suspension safely and effectively. See full prescribing information for TACLONEX Topical Suspension. TACLONEX ® (calcipotriene and betamethasone dipropionate) topical suspension Initial U.S. Approval: 2006 | LEO Pharma Inc. | LEO Laboratories Ltd. | 20171130 | 25 |
| These highlights do not include all the information needed to use Taclonex ® Ointment safely and effectively. See Full Prescribing Information for Taclonex ® Ointment. Taclonex ® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment For topical use only Initial U.S. Approval: 2006. | Physicians Total Care, Inc. | 20120529 | 4 |
| These highlights do not include all the information needed to use Taclonex Scalp® Topical Suspension safely and effectively. See full prescribing information for Taclonex Scalp® Topical Suspension. Initial U.S. Approval: 2006 | Physicians Total Care, Inc. | 20100818 | 1 |
| Dovonex ® (calcipotriene cream) Cream, 0.005% | Physicians Total Care, Inc. | 20091125 | 1 |
| 1c02cc96-ecaa-467b-9acb-7cae57ec8e87 | Physicians Total Care, Inc. | 20090914 | 4 |